Related Experiment Video
Updated: Jul 15, 2026
11:10
Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Plasma glicentin in diabetic and gastrectomized patients
1First Department of Surgery, Tohoku University School of Medicine, Miyagi, Japan.
Regulatory Peptides
|February 4, 1999
Summary
This study developed a new assay to measure human glicentin in plasma. Elevated plasma glicentin was observed in diabetic patients with renal failure and after glucose loads in certain patient groups.
Area of Science:
- Endocrinology
- Gastroenterology
- Immunology
Background:
- Human glicentin, a gastrointestinal hormone, has been successfully synthesized.
- Previous studies have investigated gut glucagon-like immunoreactive materials (GLI) or enteroglucagon.
- Understanding glicentin's role requires accurate measurement in biological samples.
Purpose of the Study:
- To establish a reliable immunoassay for quantifying human glicentin in plasma.
- To determine basal and stimulated plasma glicentin levels in various physiological and pathological conditions.
- To elucidate the secretion patterns of human glicentin in response to glucose.
Main Methods:
- Development and application of a novel sandwich enzyme-linked immunosorbent assay (ELISA).
- Measurement of plasma glicentin levels in healthy individuals, diabetic patients, and patients with specific gastrointestinal conditions.
- Analysis of plasma glicentin response to an oral glucose load.
Main Results:
- Mean fasting plasma glicentin levels were similar in normal subjects (18.6 pM) and diabetic patients (19.7 pM).
- Significantly elevated plasma glicentin (>100 pM) was found in diabetic patients with renal failure.
- Plasma glicentin showed dynamic changes after oral glucose load, with distinct patterns in normal subjects, post-gastrectomy patients, and short bowel syndrome patients.
Conclusions:
- Human glicentin can be reliably measured in plasma using the developed sandwich ELISA.
- Glicentin secretion is influenced by glucose load and is altered in conditions like renal failure and post-gastrectomy.
- These findings support the conclusion that glicentin is secreted by the small intestine in response to intraluminal glucose stimulation in humans.
More Related Videos
![Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F50301.jpg&w=3840&q=50)
12:24Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test
Published on: March 23, 2013
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...